Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

Circulation

Volumn 102, Issue 23, 2000, Pages 2836-2841

  Rothman, R B ^a   Baumann, M H ^a   Savage, J E ^a   Rauser, L ^a   McBride, A ^a   Hufeisen, S J ^a   Roth, B L ^a  

^a NONE   (United States)

Author keywords

Fenfluramine; Norfenfluramine; Receptors; Valves

Indexed keywords

ERGOTAMINE; FENFLURAMINE; METHYLERGOMETRINE; METHYSERGIDE; NORFENFLURAMINE; RECEPTOR SUBTYPE; SEROTONIN 2B RECEPTOR;

ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; MENTAL DISEASE; MITOGENESIS; PRIORITY JOURNAL; VALVULAR HEART DISEASE;

EID: 0034610435     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.23.2836     Document Type: Article

References (34)

1. Valvular heart disease associated with fenfluramine-phentermine
2. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo
3. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication
4. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine
5. Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valve abnormalities
6. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs
7. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
8. Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days
9. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications
10. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine
11. Appetite suppressants and valvular heart disease
12. Aminorex to fen/phen: An epidemic foretold
13. Chronic treatment with the phentermine combined with fenfluramine lowers plasma serotonin
14. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein
15. Pharmacokinetics of methysergide and its metabolite methylergometrine in man
16. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy
17. Aortic and mitral valve disease induced by ergotamine therapy for migraine: A case report and review of the literature
18. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)
19. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats
20. 2-Substituted tryptamines: Agents with selectivity for 5-HT(6) serotonin receptors
21. PDSP binding assay page
22. Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors
23. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: Evidence in favor of a modified ternary complex model
24. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): Where structure meets function
25. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on haman 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines
26. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor
27. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells
28. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades
29. Complications of methysergide therapy: Retroperitoneal fibrosis, mitral regurgitation, edema, and hemolytic anemia
30. Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients
31. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: Relationship to clinical improvement
32. Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium
33. Carcinoid heart disease: Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography
34. Synergistic interactions between fenfluramine and phentermine